Cisplatin and 5-fluorouracil with or without epidermal growth factor receptor inhibition panitumumab for patients with non-resectable, advanced or metastatic oesophageal squamous cell cancer: a prospective, open-label, randomised phase III AIO/EORTC trial (POWER)

Moehler, M. ; Maderer, A. ; Thuss-Patience, P.C. ; Brenner, B. ; Meiler, J. ; Ettrich, T.J. ; Hofheinz, R.-D. ; Al-Batran, S.E. ; Vogel, A. ; Mueller, L. ; Lutz, M.P. ; Lordick, F. ; Alsina, M. ; Borchert, K. ; Greil, R. ; Eisterer, W. ; Schad, A. ; Slotta-Huspenina, J. ; Van Cutsem, E. ; Lorenzen, S.

Annals of oncology, 2020-02, Vol.31 (2), p.228-235 [Periódico revisado por pares]

England: Elsevier Ltd

Texto completo disponível